Will DTC Advertising Appear In Europe? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Will DTC Advertising Appear In Europe?
Direct-to-consumer (DTC) advertising is firmly entrenched in the US, but has historically been considered as an inappropriate means of communication in Europe for prescription-only medicines. With European patients demanding more information on medicines, coupled with potential new legislation, will DTC finally gain a foothold in Europe?


Pharmaceutical Technology Europe
Volume 23, Issue 1

Over the past 2 years there has been an overt drive by the European Parliament to improve patient access to information on medicines. However, there is growing concern that some of the proposals put forward will lead to direct-to-consumer (DTC) advertising.1 Historically, in Europe, DTC has been considered an inappropriate means for pharma companies to communicate with patients because it bypasses the healthcare professional.

DTC in the US

In the US, DTC advertising is firmly entrenched, characterised by low government intervention in the market. Historically, advertising was always directed at healthcare professionals, but the increasing involvement of patients in healthcare decisions prompted some companies to change tactics.2 The first print DTC advertisement in the US appeared in 1981 from Boots for its ibuprofen product, Rufen. This was shortly followed by a similar approach from Merck for Pneumovax, its pneumonia vaccine.

These developments took the FDA by surprise and it was forced to quickly react to the situation. In 1982, the agency asked pharma companies for a voluntary moratorium on DTC advertisements while it researched the issue. Its surveys revealed a desire from patients for more information about medicines, so in 1985 the agency decided that DTC was permissible provided that it met the same legal requirements as advertising directed at healthcare professionals. At this stage, DTC took off and with time the number of promotional routes increased to take in radio and television.

One of the main problems for the FDA was that official regulations were not designed to cover advertising. The 1906 Food and Drugs Act, which represented the basis of future regulations, only focused on the information provided on the medicine's label — advertising was never specifically mentioned. Another issue was that the advertising itself was under the jurisdiction of the Federal Trade Commission (FTC), which could only act if a company's promotional advertising adversely affected that of another company. Deceptive advertising itself was not covered.

It was only in the early 1960s that regulatory authority over prescription drug advertising was transferred from the FTC to the FDA. Within the FDA, drug advertising is now regulated by the Division of Drug Marketing, Advertising and Communications (DDMAC); however, no official regulations specifically mention DTC. This vagueness effectively means that the agency has been playing catch up in trying to regulate novel advertising developments. The appearance of the internet as a promotional channel is one such example.


The author says...
Despite its existence, DTC advertising has a number of opponents in the US. For a start, many observers do not like the fact that it is difficult to determine exactly how much is being spent by the pharma industry on such promotional measures.3 When dealing with the media, the pharma industry likes to stress its investment in R&D, but while stating that promotion is vital to its work, the industry appears reluctant to provide financial figures.

Those who favour DTC believe that it heightens patient interest in their health and brings them information on new products that they might otherwise not know about.4 Others, however, believe that pharma companies do not provide impartial information, which puts the physician under pressure when a patient asks about a product they have seen advertised. Also, many consumer groups believe that drug prices are becoming too high, fuelled by DTC.

Outside the US, New Zealand, Bangladesh and South Korea allow limited DTC advertising, while in some other markets limited advertising has been permitted for certain vaccines.5 Most attention, however, has been on whether Europe will ever permit DTC — particularly as European regulators have often adapted a number of US regulations for the region.

DTC advertising for Europe?

Previous efforts to introduce DTC approaches in Europe have been rejected. In 2002, the EC introduced a proposal to allow pharma companies to answer patient requests in three disease areas: diabetes, asthma and HIV/AIDS.6,7 The intention was to allow a 3year trial period, but these measures were strongly rejected by the European Parliament. Surprisingly, the measures were also rejected by the pharma industry, which made it clear that it had not sought to change the existing regulations regarding the direct provision of information to patients. Nevertheless, the industry did use the opportunity to express irritation in the way it was monitored. For example, it asked why specific laws stood in the way of it communicating with patients over its products, even when others could. Presumably, this meant information communicated by the media about new medicines. In this regard, the restrictions on the pharma industry contrast with the freedom enjoyed by manufacturers of vitamins and herbal remedies, who routinely advertise products to patients. The pharma industry also asked why companies manufacturing foods containing unhealthy ingredients were not prevented from freely communicating with the public.

While not advocating DTC advertising outright, the European pharma industry has consistently held the position that in a regulated environment there should be some means for companies to communicate directly with patients regarding their medicines. Given the carefully worded statements from the pharma industry suggesting that it is not openly seeking change, it is therefore surprising that DTC proposals continue to be put forward for debate in the European Parliament.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
17%
Protecting the supply chain
50%
Expedited reviews of drug submissions
0%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Source: Pharmaceutical Technology Europe,
Click here